{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:15:47Z","timestamp":1790615747512,"version":"4.1.0"},"reference-count":35,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T00:00:00Z","timestamp":1764115200000},"content-version":"unspecified","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Gastroenterol"],"accepted":{"date-parts":[[2025,10,27]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest solid tumours, with 5-year survival consistently below 10% and only modest gains from conventional chemotherapy after first-line failure. Although oncogenic\n                    <jats:italic>KRAS<\/jats:italic>\n                    mutations dominate the genomic landscape, recent large-scale sequencing has revealed a series of less frequent but therapeutically actionable alterations. This review synthesises evidence from phase I\u2013II trials published through April 2025. It demonstrates that targeting these lesions can yield outcomes that meet or exceed the benchmarks set by the NAPOLI-1 trial (liposomal irinotecan plus 5-fluorouracil and leucovorin), with a median overall survival of 6.2 months and progression-free survival of 3.1 months. Objective response rates reach 33% with adagrasib in\n                    <jats:italic>KRAS G12C<\/jats:italic>\n                    PDAC, 22% with olaparib maintenance in germline BRCA1\/2 cancers, and over 50% with RET or NTRK inhibitors with fusion alterations; pembrolizumab produces durable benefit in the 1\u20133% of tumours that are MSI-H\/dMMR. Emerging data highlight NRG1 fusions (overall response rate 42% with zenocutuzumab), HER2 amplification, MTAP deletion with PRMT5 dependency and variant-specific (MRTX1133) or pan-RAS (daraxonrasib) inhibitors as the next frontier. Toxicity profiles of targeted agents are generally favourable and often allow prolonged administration compared with cytotoxic regimens. Taken together, these advances represent a substantive therapeutic progress in PDAC over the past decades, even though they currently apply to a minority of patients. These findings underscore the necessity of comprehensive next-generation sequencing for every patient with advanced disease, enabling identification of rare, yet clinically meaningful, targets and moving PDAC management towards a precision-oncology paradigm.\n                  <\/jats:p>","DOI":"10.1136\/bmjgast-2025-001925","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:50:11Z","timestamp":1764251411000},"page":"e001925","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":9,"title":["Actionable mutations in pancreatic cancer: where targeted therapies are making a difference"],"prefix":"10.1136","volume":"12","author":[{"given":"Morgan","family":"Fivaz","sequence":"first","affiliation":[{"name":"Oncology Department, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Bornand","sequence":"additional","affiliation":[{"name":"Pathology Department, Geneva University Hospital, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Corro","sequence":"additional","affiliation":[{"name":"Oncology Department, Geneva University Hospital, Geneva, Switzerland"},{"name":"Department of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Koessler","sequence":"additional","affiliation":[{"name":"Oncology Department, Geneva University Hospital, Geneva, Switzerland"},{"name":"Department of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5351-3043","authenticated-orcid":false,"given":"Vassilis","family":"Genoud","sequence":"additional","affiliation":[{"name":"Oncology Department, Geneva University Hospital, Geneva, Switzerland"},{"name":"Department of Medicine, University of Geneva, Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,27]]},"reference":[{"key":"2025112705500695000_12.1.e001925.1","doi-asserted-by":"crossref","DOI":"10.3389\/or.2023.11364","article-title":"Metastatic Pancreatic Cancer: Where Are We?","volume":"17","author":"Hern\u00e1ndez-Blanquisett","year":"2023","journal-title":"Oncol Rev"},{"key":"2025112705500695000_12.1.e001925.2","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.3390\/biomedicines12102175","article-title":"Targeted Therapies in Pancreatic Cancer: A New Era of Precision Medicine","volume":"12","author":"Li","year":"2024","journal-title":"Biomedicines"},{"key":"2025112705500695000_12.1.e001925.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.02.014"},{"key":"2025112705500695000_12.1.e001925.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00986-1"},{"key":"2025112705500695000_12.1.e001925.5","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.53588","article-title":"KRAS Mutation Status and Treatment Outcomes in Patients With Metastatic Pancreatic Adenocarcinoma","volume":"8","author":"Norton","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2025112705500695000_12.1.e001925.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208470"},{"key":"2025112705500695000_12.1.e001925.7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00434"},{"key":"2025112705500695000_12.1.e001925.8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/cancers14040897","article-title":"Precision Medicine for BRCA\/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition","volume":"14","author":"Principe","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2025112705500695000_12.1.e001925.9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s40164-025-00673-0","article-title":"Homologous recombination-DNA damage response defects increase TMB and neoantigen load, but not effector T cell density and clonal diversity in pancreatic cancer","volume":"14","author":"Lei","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"2025112705500695000_12.1.e001925.10","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2025.1570731","article-title":"Prognostic impact of gene alterations via homologous recombination DNA repair gene alteration status in pancreatic ductal adenocarcinoma","volume":"12","author":"Kawanaka","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"2025112705500695000_12.1.e001925.11","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.3390\/cancers16203447","article-title":"PARP Inhibitors in Pancreatic Cancer with Homologous Recombination Repair Gene Mutations: A Single-Institution Experience","volume":"16","author":"Miao","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2025112705500695000_12.1.e001925.12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2728"},{"key":"2025112705500695000_12.1.e001925.13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01604"},{"key":"2025112705500695000_12.1.e001925.14","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1158\/1541-7786.MCR-22-0626","article-title":"BRAF-Driven Pancreatic Cancer: Prevalence, Molecular Features, and Therapeutic Opportunities","volume":"21","author":"Ciner","year":"2023","journal-title":"Mol Cancer Res"},{"key":"2025112705500695000_12.1.e001925.15","doi-asserted-by":"crossref","first-page":"102447","DOI":"10.1016\/j.eclinm.2024.102447","article-title":"Dabrafenib and trametinib administration in patients with BRAF V600E\/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial","volume":"69","author":"Shimoi","year":"2024","journal-title":"eClinicalMedicine"},{"key":"2025112705500695000_12.1.e001925.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.05.519"},{"key":"2025112705500695000_12.1.e001925.17","doi-asserted-by":"publisher","DOI":"10.1136\/jclinpath-2021-207781"},{"key":"2025112705500695000_12.1.e001925.18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714448"},{"key":"2025112705500695000_12.1.e001925.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30856-3"},{"key":"2025112705500695000_12.1.e001925.20","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30691-6"},{"key":"2025112705500695000_12.1.e001925.21","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","article-title":"Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors","volume":"28","author":"Demetri","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025112705500695000_12.1.e001925.22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00541-1"},{"key":"2025112705500695000_12.1.e001925.23","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1200\/JCO.2024.42.3_suppl.746","article-title":"Durable efficacy of selpercatinib in patients with RET fusion+ solid tumors, with a focus on GI tumors: LIBRETTO-001","volume":"42","author":"Subbiah","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025112705500695000_12.1.e001925.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01931-y"},{"key":"2025112705500695000_12.1.e001925.25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1339302","article-title":"ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition","volume":"14","author":"Barzi","year":"2024","journal-title":"Front Oncol"},{"key":"2025112705500695000_12.1.e001925.26","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/diagnostics11040653","article-title":"The Prognostic Impact of HER2 Genetic and Protein Expression in Pancreatic Carcinoma\u2014HER2 Protein and Gene in Pancreatic Cancer","volume":"11","author":"Han","year":"2021","journal-title":"Diagnostics (Basel)"},{"key":"2025112705500695000_12.1.e001925.27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.22.02636","article-title":"MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2\u2013Altered Advanced Solid Tumors","volume":"42","author":"Sweeney","year":"2024","journal-title":"J Clin Oncol"},{"key":"2025112705500695000_12.1.e001925.28","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02005"},{"key":"2025112705500695000_12.1.e001925.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.08.2335"},{"key":"2025112705500695000_12.1.e001925.30","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa2405008","article-title":"Efficacy of Zenocutuzumab in NRG1 Fusion\u2013Positive Cancer","volume":"392","author":"Schram","year":"2025","journal-title":"N Engl J Med"},{"key":"2025112705500695000_12.1.e001925.31","unstructured":"Research C for DE and . FDA grants accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma. FDA; 2024. Available: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zenocutuzumab-zbco-non-small-cell-lung-cancer-and-pancreatic"},{"key":"2025112705500695000_12.1.e001925.32","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/s41571-025-01005-1","article-title":"Zenocutuzumab shows efficacy in NRG1 fusion-positive solid tumours","volume":"22","author":"Romero","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2025112705500695000_12.1.e001925.33","doi-asserted-by":"crossref","first-page":"104535","DOI":"10.1016\/j.esmoop.2025.104535","article-title":"Pan-cancer clinical and molecular landscape of MTAP deletion in nationwide and international comprehensive genomic data","volume":"10","author":"Ikushima","year":"2025","journal-title":"ESMO Open"},{"key":"2025112705500695000_12.1.e001925.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02007-7"},{"key":"2025112705500695000_12.1.e001925.35","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.4_suppl.722"}],"container-title":["BMJ Open Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgast-2025-001925","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T13:50:16Z","timestamp":1764251416000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopengastro.bmj.com\/lookup\/doi\/10.1136\/bmjgast-2025-001925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,11,27]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjgast-2025-001925"],"URL":"https:\/\/doi.org\/10.1136\/bmjgast-2025-001925","relation":{},"ISSN":["2054-4774"],"issn-type":[{"value":"2054-4774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}